Edesa Biotech (EDSA) Competitors $2.38 -0.12 (-4.80%) Closing price 02/21/2025 03:58 PM EasternExtended Trading$2.38 +0.00 (+0.21%) As of 02/21/2025 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends EDSA vs. TRAW, CYTH, CVM, TENX, XCUR, NAII, CGTX, FNCH, ALLK, and LVTXShould you be buying Edesa Biotech stock or one of its competitors? The main competitors of Edesa Biotech include Traws Pharma (TRAW), Cyclo Therapeutics (CYTH), CEL-SCI (CVM), Tenax Therapeutics (TENX), Exicure (XCUR), Natural Alternatives International (NAII), Cognition Therapeutics (CGTX), Finch Therapeutics Group (FNCH), Allakos (ALLK), and LAVA Therapeutics (LVTX). These companies are all part of the "pharmaceutical products" industry. Edesa Biotech vs. Traws Pharma Cyclo Therapeutics CEL-SCI Tenax Therapeutics Exicure Natural Alternatives International Cognition Therapeutics Finch Therapeutics Group Allakos LAVA Therapeutics Traws Pharma (NASDAQ:TRAW) and Edesa Biotech (NASDAQ:EDSA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, community ranking, media sentiment and profitability. Do analysts prefer TRAW or EDSA? Edesa Biotech has a consensus target price of $21.00, indicating a potential upside of 782.35%. Given Edesa Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Edesa Biotech is more favorable than Traws Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Traws Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Edesa Biotech 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, TRAW or EDSA? Traws Pharma has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500. Comparatively, Edesa Biotech has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500. Does the MarketBeat Community favor TRAW or EDSA? Edesa Biotech received 27 more outperform votes than Traws Pharma when rated by MarketBeat users. CompanyUnderperformOutperformTraws PharmaN/AN/AEdesa BiotechOutperform Votes2777.14% Underperform Votes822.86% Do insiders & institutionals believe in TRAW or EDSA? 8.0% of Traws Pharma shares are owned by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are owned by institutional investors. 13.6% of Traws Pharma shares are owned by company insiders. Comparatively, 25.0% of Edesa Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the media prefer TRAW or EDSA? In the previous week, Traws Pharma had 2 more articles in the media than Edesa Biotech. MarketBeat recorded 2 mentions for Traws Pharma and 0 mentions for Edesa Biotech. Traws Pharma's average media sentiment score of 0.00 equaled Edesa Biotech'saverage media sentiment score. Company Overall Sentiment Traws Pharma Neutral Edesa Biotech Neutral Is TRAW or EDSA more profitable? Edesa Biotech has a net margin of 0.00% compared to Traws Pharma's net margin of -62,294.25%. Traws Pharma's return on equity of 0.00% beat Edesa Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Traws Pharma-62,294.25% N/A -822.38% Edesa Biotech N/A -233.69%-124.14% Which has stronger earnings and valuation, TRAW or EDSA? Edesa Biotech has lower revenue, but higher earnings than Traws Pharma. Edesa Biotech is trading at a lower price-to-earnings ratio than Traws Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTraws Pharma$230K71.10-$18.95M-$141.56-0.03Edesa BiotechN/AN/A-$6.17M-$1.87-1.27 SummaryEdesa Biotech beats Traws Pharma on 9 of the 15 factors compared between the two stocks. Get Edesa Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for EDSA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EDSA vs. The Competition Export to ExcelMetricEdesa BiotechPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.34M$7.06B$5.84B$9.15BDividend YieldN/A2.75%4.75%3.85%P/E Ratio-1.275.8226.1519.13Price / SalesN/A268.05435.3370.72Price / CashN/A65.6738.0134.83Price / Book13.226.717.644.62Net Income-$6.17M$138.55M$3.19B$245.94M7 Day Performance-11.52%-2.63%-2.11%-2.62%1 Month Performance32.30%-2.33%-0.49%-2.15%1 Year Performance-50.10%-5.33%16.44%12.95% Edesa Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EDSAEdesa Biotech2.6638 of 5 stars$2.38-4.8%$21.00+782.4%-53.9%$17.34MN/A-1.2720Earnings ReportTRAWTraws Pharma0.5212 of 5 stars$7.35-7.5%N/AN/A$26.84M$226,000.00-0.0517News CoverageGap DownCYTHCyclo Therapeutics0.9525 of 5 stars$0.93-22.0%$0.95+2.4%-45.8%$26.70M$1.08M-1.039News CoverageGap DownCVMCEL-SCIN/A$0.36-5.1%N/A-81.5%$26.65MN/A-0.7143News CoverageTENXTenax Therapeutics1.9324 of 5 stars$7.76+7.3%$16.00+106.2%+55.2%$26.46MN/A0.009News CoverageGap UpHigh Trading VolumeXCURExicure1.2717 of 5 stars$10.14-1.6%N/A+1,352.1%$26.45M$28.83M-4.9050NAIINatural Alternatives International0.3762 of 5 stars$4.21+0.2%N/A-30.4%$26.10M$113.80M-2.92290Earnings ReportAnalyst ForecastCGTXCognition Therapeutics3.3265 of 5 stars$0.60-5.6%$8.30+1,285.2%-70.7%$24.90MN/A-0.6220News CoverageFNCHFinch Therapeutics GroupN/A$15.38+28.2%N/A+537.1%$24.76M$110,000.00-1.74190News CoverageHigh Trading VolumeALLKAllakos4.225 of 5 stars$0.27+0.3%$2.00+632.3%-77.8%$24.40MN/A-0.13190LVTXLAVA Therapeutics2.9368 of 5 stars$0.91-4.6%$3.33+265.6%-50.9%$23.97M$6.77M-0.8960Gap Up Related Companies and Tools Related Companies TRAW Competitors CYTH Competitors CVM Competitors TENX Competitors XCUR Competitors NAII Competitors CGTX Competitors FNCH Competitors ALLK Competitors LVTX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:EDSA) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersEx-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000”Experts forecast gold's price racing to $4,000… and an ex-CIA advisor predicts we'll see gold hit $10,000. ...Colonial Metals | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edesa Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Edesa Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
